• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

12-gene Recurrence Score can inform adjuvant therapy of colon cancer

byAndrew Bishara
November 16, 2013
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD  Oxaliplatin

1. The 12-gene Recurrence Score can predict recurrence risk and disease-free survival in both stage II and III colon cancer.

2. Higher scores may help predict absolute benefit of oxaliplatin for stage II and IIIA/B disease.

Evidence rating level:  2 (Good)

Study Rundown: Given the complex treatment options available for patients diagnosed with stage II or III colon cancer, accurate assessments of risk for recurrence may help to inform the management decisions of these patients. The 12-gene Recurrence Score assay has been previously validated in patients with stage II colon cancer. Therefore, the purpose of this study was to retrospectively determine the efficacy of this assay in patients with stage II and III colon cancer.

At the conclusion of the study, the authors determined that Recurrence Score predicted recurrence risk, as well as disease-free and overall survival in stage II and III colon cancer. Furthermore, they also concluded that the absolute benefit of oxaliplatin increased with higher scores, particularly in patients with stage II and IIIA/B disease. On the basis of these findings, the authors recommended that this assay be included in the clinical management of these patients in order to better inform adjuvant therapy decision-making. These conclusions are strengthened by the large sample sizes used in this study. However, it should be noted that the use of specimens from patients enrolled in previous clinical trials (National Surgical Adjuvant Breast and Bowel Project C-07) may limit the generalizability of these findings.

RELATED REPORTS

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer

Click to read the article in JCO

Relevant reading: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin

In-Depth [retrospective cohort study]: This clinical validation study of the 12-gene Recurrence Score assay was a prospectively designed review with pre-specified end points and analysis plan of archival tumor specimens. The specimens came from patients with stage II and III colon cancer randomly assigned to either fluorouracil (FU) or FU plus oxaliplatin in the National Surgical Adjuvant Breast and Bowel project. A total of 892 tumor specimens were examined and Recurrence Score calculated.

The study authors found that the Recurrence Score predicted recurrence (P < 0.001) as well as disease-free and overall survival ((P < 0.001). Its association with recurrence risk remained after adjustment for stage, mismatch repair, lymph nodes examined, grade and treatment. The relative benefit of oxaliplatin in addition to FU adjuvant therapy was similar across the range of Recurrence scores (P = 0.48); therefore, the authors concluded that the absolute benefit of oxaliplatin increased with higher scores, particularly in patients with stage II and IIIA/B disease.

By Monica Parks and Andrew Bishara

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

 

Tags: adjuvant therapychemotherapycolon canceroxaliplatinrecurrence riskstage II and IIIA/B cancer
Previous Post

Text messaging program for diabetes shows improved medication adherence

Next Post

Multiple births associated with increased healthcare costs

RelatedReports

Reduced gestational weight gain with lifestyle intervention
Chronic Disease

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer

July 2, 2025
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

June 19, 2025
#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
StudyGraphics

#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer

June 13, 2025
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Pharma

2 Minute Medicine: Pharma Roundup – Perioperative Immunotherapy Efficacy, Expanded Prostate Cancer Indication, Rapid Subcutaneous Myeloma Administration, and Regulatory Compliance Findings [June 4 2025]

June 4, 2025
Next Post
Obtaining consent for c-section during labor may be suboptimal

Multiple births associated with increased healthcare costs

IUD contraception equally safe in teenagers as in older women

Lower-dose levonorgestrel IUD effective, well-tolerated

Early retroviral therapy reduces HIV-1 transmission [Classics Series]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.